Skip to main content
Fig. 1 | Cellular & Molecular Biology Letters

Fig. 1

From: Upregulation of miR-361-3p suppresses serotonin-induced proliferation in human pulmonary artery smooth muscle cells by targeting SERT

Fig. 1

The miR-361-3p expression profile in the plasma of PAH patients and in hPASMCs treated with serotonin. a Relative expression level of miR-361-3p in the plasma of PAH patients and normal control subjects. Correlation of miR-361-3p with mean pulmonary arterial pressure (b), pulmonary vascular resistance (c) and pulmonary vascular resistance index (d). e The OD490nm value of PASMCs treated with 0, 50, 100, 250, 500 and 1000 μmol/l serotonin for 24, 48 and 72 h. The MTS assay was performed and the OD490nm was measured. *p < 0.05, when compared to results for 0 μmol/l. f miR-361-3p level in hPASMCs treated with 250 μmol/l serotonin (serotonin) or not treated (blank) for 48 h. The miR-361-3p level was determined using quantitative RT-PCR. *p < 0.05, serotonin group vs. blank group

Back to article page